Targeted Genetics regulatory update

TGEN said U.S. Patent No. 5,470,726 issued covering the PG13 retrovirus packaging cell line for use in gene therapy. The patent, which is co-owned by the Fred Hutchinson Cancer Research Center and the National Institutes of Health, is exclusively licensed to TGEN. ...